U.S. markets closed

VistaGen Therapeutics, Inc. (VTGN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.1520+0.0009 (+0.60%)
At close: 04:00PM EDT
0.1540 +0.00 (+1.32%)
After hours: 05:57PM EDT

VistaGen Therapeutics, Inc.

343 Allerton Avenue
South San Francisco, CA 94080
United States
650 577 3600

Full Time Employees38

Key Executives

NameTitlePayExercisedYear Born
Mr. Shawn K. Singh J.D.CEO & Director912.5kN/A1963
Mr. Jerrold D. Dotson CPA, CPACFO, VP & Sec.577.5kN/A1953
Mr. Reid G. Adler Esq., J.D.Chief Legal OfficerN/AN/A1954
Dr. Mark A. Smith M.D., Ph.D.Chief Medical Officer658.75kN/A1955
Ms. Ann Michelle Cunningham M.B.A.Chief Commercial Officer & Director576.44kN/A1968
Mr. Mark FlatherVP of Investor RelationsN/AN/AN/A
Mr. Mark Adrian McPartlandVP of Corp. Devel.N/AN/A1966
Ms. Trisha FitzmauriceVP of HRN/AN/AN/A
Dr. Allen Easley Cato III, M.D., Ph.D.Sr. VP of Devel. OperationsN/AN/AN/A
Dr. Mark J. GinskiSr. VP and Head of Chemistry, Manufacturing & ControlsN/AN/A1972
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, and panic disorders. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with oral probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license agreement with Pherin Pharmaceuticals, Inc.; and license and collaboration agreement with EverInsight Therapeutics Inc. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

Corporate Governance

VistaGen Therapeutics, Inc.’s ISS Governance QualityScore as of September 1, 2022 is 7. The pillar scores are Audit: 10; Board: 7; Shareholder Rights: 3; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.